SEC Tracker
Get the app
RTGN · XBRL financial data

RetinalGenix Technologies financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (RTGN's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development—year only8383103104*13142035*11766
General and administrative167408*329369244392*341384270306*262212
Total operating expenses686541*2,145663643866*586648568622*589303
Interest expense11*1111*1111*14
Net income (loss)(686)(542)*(2,146)(664)(644)(867)*(587)(649)(569)(623)*(590)(307)
Earnings per share, basic USD per share(0.04)(0.03)*(0.12)(0.04)(0.04)(0.05)*(0.03)(0.03)(0.03)(0.03)*(0.03)(0.02)
Earnings per share, diluted USD per share(0.04)(0.03)*(0.12)(0.04)(0.04)(0.05)*(0.03)(0.03)(0.03)(0.03)*(0.03)(0.02)
Weighted average shares, basic thousands of shares17,27617,586*17,67217,86417,97018,253*18,52218,32718,58018,818*18,75518,808
Weighted average shares, diluted thousands of shares17,27617,586*17,67217,86417,97018,253*18,52218,32718,58018,818*18,75518,808

Balance sheet

CSV

Fiscal quarters (RTGN's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents00508779641015027
Total current assets00508779641015027
Property and equipment, net0000000—————
Right-of-use asset————87665443
Total assets0051878915128721632
Total current liabilities—1,406——1,9361,4711,6731,9832,1742,3202,5612,670
Lease liability, non-current————77666433
Total liabilities1,0831,4061,5691,8981,9431,4781,6801,9902,1802,3242,5642,673
Accumulated deficit(10,568)(11,109)(13,255)(13,919)(14,563)(15,430)(16,017)(16,667)(17,235)(17,859)(18,449)(18,757)
Total stockholders' equity(1,083)(1,406)(1,519)(1,811)(1,854)(1,463)(1,668)(1,981)(2,173)(2,303)(2,558)(2,641)
Total liabilities and equity0051878915128721632
Common shares outstanding (cover page) thousands of shares17,58917,78517,86017,99618,09118,52218,52218,60518,60518,75518,84418,844

Cash flows

CSV

Fiscal quarters (RTGN's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(686)(542)*(2,146)(664)(644)(867)*(587)(649)(569)(623)*(590)(307)
Stock-based compensation42979*1,733211296370*232250277281*21025
Net cash from operating activities40*(187)*(143)(166)*(247)*(186)*(187)(139)*(104)*(128)*(109)(137)*
Proceeds from issuing common stock————305*98*——100*212*——
Net cash from financing activities(42)*187*193202*239*113*185136*103*143*95164*
Net change in cash(2)*(0)*5037*(8)*(73)*(2)(3)*(1)*15*(15)27*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
RetinalGenix Technologies27not reported(137)*18.8M0.2 quarters 10-QJun 30, 2026
Beyond Air5,5091,768(4,946)957,6312.0 quarters 10-QJun 30, 2026
Harvard Apparatus Regenerative Technology351414(569)*17.6M0.6 quarters 10-QJun 30, 2026
Nexalin Technology1,00512(1,802)*22.0M0.6 quarters 10-QJun 30, 2026
Iridex4,68012,566174*17.6M— 10-QJul 4, 2026
Biotricity4674,27750719.9M— 10-QJun 30, 2026
VASO38,291not reported17,444*176.0M— 10-QJun 30, 2026
Envoy Medical19,67951(5,456)*77.2M3.6 quarters 10-QJun 30, 2026
Dror Ortho-Design94not reported(305)*977.0M0.3 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.